COVID-19 experts discuss exosomes and mesenchymal stem cells as experimental treatment for ARDS/COVID-19
Experts will discuss experimental treatments, including exosomes and mesenchymal stem cells, for acute respiratory distress syndrome in COVID-19 patients.
In this webinar, learn more about the ongoing research and clinical trials to manage acute respiratory distress syndrome (ARDS) in COVID-19 patients. Two experts will share their extensive experience with therapies using mesenchymal stem cells (MSCs) and the small extracellular vesicles (sEVs) that MSCs produce as potential treatments for COVID-19 patients with ARDS.
Interested in working with RegMedNet on your own campaign? Contact us today>>>
What will you learn?
- Explore how sEVs can recapitulate the therapeutic effect of MSCs
- Discuss clinical trial design with critically ill patients, such as those with COVID-19, including strategies for optimizing sample size, managing patient and disease heterogeneity, and maximizing the use of trial data
- Learn how the lung inflammatory environment may alter MSC behavior
Who might this interest?
- Regenerative medicine researchers
- Cell therapy manufacturers
- Other stakeholders in cell therapy
Professor of Medicine at the School of Medicine, University of California San Francisco (UCSF; CA, USA)
Associate Scientist in the department of Neurology at Henry Ford Health System; Adjunct Associate Professor at Oakland University; Scientific Consultant at NeurExo Sciences (all MI, USA)
Dr Buller is an Associate Scientist in the Department of Neurology at Henry Ford Health System in Detroit and he serves as an Adjunct Associate Professor at Oakland University and as a consultant at NeurExo Sciences, developing therapeutics using exosomes. He also served as Chief Scientific Officer at Forever Labs (MI, USA). Dr Buller has been pivotal in demonstrating the role of exosomes in the delivery of microRNAs to treat stroke and traumatic brain injury. In this webinar, he will discuss his investigation into the use of MSC exosomes to treat acute respiratory distress syndrome in COVID-19 patients.
In association with: